Possibia

2361138

Last Update Posted: 2015-02-11

Recruiting has ended

All Genders

accepted

18 Years-45 Years

48 Estimated Participants

No Expanded Access

Interventional Study

Accepts healthy volunteers

The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers

SHR3824 is a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study the investigators evaluated the safety, tolerability and PK/PD profiles of SHR3824 in healthy subjects.

Eligibility

Relevant conditions:

Type 2 Diabetes

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov